在怀孕期间接触epoprostenol
Emily E Naoum1, Carolyn LaVita2, Natasha Lopez3
1Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA.
Critical care explorations
|August 28, 2023
概括
目前的政策禁止孕妇医疗保健提供者照顾吸入式epoprostenol的患者缺乏数据. 审查文献可以帮助消除这些限制,确保孕妇提供者获得平等的就业和学习机会.
科学领域:
- 医疗安全 医疗安全
- 职业健康 职业健康 职业健康 职业健康
- 肺部医学 肺部医学
背景情况:
- 许多机构限制孕妇提供者照顾使用吸入式epoprostenol的患者.
- 这些限制通常基于有限的科学证据.
研究的目的:
- 审查有关吸入性epoprostenol在产科患者的安全性的文献.
- 倡导取消制度政策,限制孕妇提供者照顾接受吸入式epoprostenol的患者.
主要方法:
- 关于吸入肺血管扩展剂及其在怀孕期间的安全性研究的文献综述.
- 分析现有的机构政策及其证据基础.
主要成果:
- 在过去的二十年中,吸入性肺血管扩张剂的使用量有所增加.
- 有证据表明,这些药物对于产科患者的使用是安全的.
- 目前的限制缺乏实质性数据来支持其必要性.
结论:
- 取消对孕妇提供者照顾吸入性epoprostenol患者的限制是有必要的.
- 这种改变将减轻不必要的压力,并确保公平的就业和学习机会.
- 证据支持吸入性epoprostenol对于孕妇提供者及其患者的安全性.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
213
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
213
Teratogenicity
2.5K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.5K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
200
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
200
Hormonal Regulation
33.3K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.3K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
493
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
493
Oogenesis
63.8K
In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...
63.8K


